Diffuse Large B Cell Lymphoma Clinical Trials in Melbourne, Victoria
6 recruitingMelbourne, Victoria, Australia
Showing 1–6 of 6 trials
Recruiting
Phase 1Phase 2
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+6 more
BeOne Medicines614 enrolled120 locationsNCT05006716
Recruiting
Phase 3
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Diffuse Large B Cell Lymphoma
Merck Sharp & Dohme LLC1,046 enrolled246 locationsNCT06717347
Recruiting
Phase 1
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin's Lymphoma+1 more
AbbVie150 enrolled39 locationsNCT05618028
Recruiting
Phase 2
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Diffuse Large B Cell Lymphoma
Karyopharm Therapeutics Inc244 enrolled176 locationsNCT02227251
Recruiting
Phase 2
Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL
High-grade B-cell LymphomaDLBCL - Diffuse Large B Cell LymphomaHigh Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements+4 more
Australasian Leukaemia and Lymphoma Group39 enrolled1 locationNCT06287398
Recruiting
Phase 2
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell LymphomaRelapsed Diffuse Large B Cell Lymphoma
ImmunoVaccine Technologies, Inc. (IMV Inc.)102 enrolled50 locationsNCT04920617